One-year follow up of Thalassemia patients with Deferiprone (GPO-L-ONE) Chelation Therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20110000020

Enrollment

Unknown

Registered

2012-03-12

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult thalassemia patients with iron overload. thalassemia&#44

Interventions

adult (&#8805

15 years) thalassemia patients with iron overload&#44

serum ferritin level > 1&#44

000 &#61549

g/L.

Treatment

Deferiprone (GPO&#45

L&#45

ONE&#61666

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Adult thalassemia patients with serum ferritin level was above 1,000 ug/L. None of the patients were pregnant, without elevated aspartate transaminase (AST) or alanine transaminase (ALT) (exceeding 250 IU/L), and an absolute neutrophil count (ANC) of less than 1,500 cells/mm3. Bone marrow disease including malignancy, aplastic anemia and myelodysplastic syndrome were also excluded. No patients used other iron chelating agents. All patients had normal ophthalmic examinations and audiometry tests.

Exclusion criteria

Exclusion criteria: transaminase levels were elevated more than three times or exceeding 250 IU/L, ANC less than 1,500 cells/mm3, severe infection, drug allergy.

Design outcomes

Primary

Measure	Time frame
serum ferritin reduction 12 months serum ferritin level	—

Secondary

Measure	Time frame
adverse effects 12 months history taking and physical examination	—

Countries

Thailand

Contacts

Public ContactNonlawan Chueamuangphan

Chiang Rai Hospital

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026

One&#45;year follow up of Thalassemia patients with Deferiprone (GPO&#45;L&#45;ONE) Chelation Therapy